Related Experiment Video
Updated: Feb 14, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
PI3K-mTOR pathway identified as a potential therapeutic target in biliary tract cancer using a newly established
Yasunari Sakamoto1, Seri Yamagishi2, Yoshinori Tanizawa3
1Department of Hepatobiliary and Pancreatic Oncology, Tokyo, National Cancer Center Hospital.
Abstract:
Biliary tract carcinoma (BTC) is an extremely malignant tumor, but available treatment options are limited. Despite of needs for novel therapies, few BTC-related resources are currently available for evaluation of candidate drugs. To address this issue, we have recently established 13 cell lines from surgical specimens from Japanese BTC patients. In the present study, we evaluated four new molecular targeting agents using our BTC cell-based assay panel with 17 BTC cell lines. PI3K/mTOR dual inhibitor LY3023414 showed activity at submicromolar concentration ranges against 13 of the 17 cell lines tested, including the ones with gemcitabine insensitivity. In conclusion, we demonstrated that in vitro study with the BTC cell line panel would be an efficient approach to screen for novel therapeutic strategies. Although this is preliminary result and further investigations are required for confirmation, PI3K/mTOR inhibitor might be a potential target for BTC drug development.
Insights
Novel therapies for biliary tract carcinoma (BTC) are needed. A PI3K/mTOR dual inhibitor demonstrated significant activity against 13 of 17 BTC cell lines, suggesting its potential for drug development.
Area of Science:
- Oncology
- Drug Discovery
- Gastroenterology
Background:
- Biliary tract carcinoma (BTC) is a highly malignant cancer with limited treatment options.
- There is a critical need for novel therapeutic strategies and accessible resources for drug evaluation in BTC.
- Existing BTC models are insufficient for comprehensive preclinical drug screening.
Purpose of the Study:
- To establish and utilize a panel of Japanese biliary tract carcinoma cell lines for drug screening.
- To evaluate the efficacy of four novel molecular targeting agents against BTC.
- To identify promising therapeutic targets for biliary tract carcinoma.
Main Methods:
- Establishment of 13 new cell lines from surgical specimens of Japanese BTC patients.
- In vitro evaluation of four molecular targeting agents using a panel of 17 BTC cell lines.
- Assessment of drug activity at submicromolar concentration ranges.
Main Results:
- The PI3K/mTOR dual inhibitor LY3023414 exhibited potent activity against 13 out of 17 BTC cell lines.
- Activity was observed even in cell lines resistant to gemcitabine.
- The BTC cell line panel proved effective for screening novel therapeutic agents.
Conclusions:
- An in vitro study using a biliary tract carcinoma cell line panel is an efficient method for screening novel therapeutic strategies.
- PI3K/mTOR dual inhibitors represent a potential therapeutic target for biliary tract carcinoma drug development.
- Further investigation is warranted to confirm these preliminary findings.
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Cell Potential and Free Energy
Thermodynamics is the branch of physics dealing with the relationship between heat and other forms of energy. In an electrochemical cell, chemical energy is converted into electrical energy.
Thus, a link can be predicted between cell potential, free energy change, and the equilibrium constant for the reaction. Cell potential can also be measured as the oxidant or the reducing strength, and similar acid-base strength measures are reflected in equilibrium...
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Wood Panel Products

